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OBJECTIVES—This study aimed to identify clinical features
associated with premature mortality in a large contemporary
cohort of adults with type 1 diabetes.
RESEARCH DESIGN AND METHODS—The Finnish Diabetic
Nephropathy (FinnDiane) study is a national multicenter pro-
spective follow-up study of 4,201 adults with type 1 diabetes from
21 university and central hospitals, 33 district hospitals, and 26
primary health care centers across Finland.
RESULTS—During a median 7 years of follow-up, there were
291 deaths (7%), 3.6-fold (95% CI 3.2–4.0) more than that ob-
served in the age- and sex-matched general population. Excess
mortality was only observed in individuals with chronic kidney
disease. Individuals with normoalbuminuria showed no excess
mortality beyond the general population (standardized mortality
ratio [SMR] 0.8, 95% CI 0.5–1.1), independent of the duration of
diabetes. The presence of microalbuminuria, macroalbuminuria,
and end-stage kidney disease was associated with 2.8, 9.2, and
18.3 times higher SMR, respectively. The increase in mortality
across each stage of albuminuria was equivalent to the risk
conferred by preexisting macrovascular disease. In addition, the
glomerular ﬁltration rate was independently associated with
mortality, such that individuals with impaired kidney function, as
well as those demonstrating hyperﬁltration, had an increased
risk of death.
CONCLUSIONS—An independent graded association was ob-
served between the presence and severity of kidney disease and
mortality in a large contemporary cohort of individuals with type
1 diabetes. These ﬁndings highlight the clinical and public health
importance of chronic kidney disease and its prevention in the
management of type 1 diabetes. Diabetes 58:1651–1658, 2009
D
espite modern therapeutics, type 1 diabetes
continues to be associated with premature
death. For example, mortality in individuals
with type 1 diabetes from Finland is 3–4 times
higher than in the general population (1). However, not all
individuals with type 1 diabetes share this risk. In order to
determine the current prognosis of any individual with
type 1 diabetes and direct preventive interventions, it is
important to identify those individuals at increased risk of
death.
Chronic kidney disease is a common complication of
type 1 diabetes, affecting up to 30% of patients (2).
Previous studies have identiﬁed chronic kidney disease
as a risk factor for mortality in type 1 diabetes (3–6).
However, many of these observations were made when
current management paradigms, including intensiﬁed met-
abolic control and blockade of the renin angiotensin
system, were not widely applied. In this article, we exam-
ine the incidence and predictors of all-cause mortality in a
nationally representative cohort of adults with type 1
diabetes, showing that the presence and severity of
chronic kidney disease remains the major determinant of
excess mortality associated with type 1 diabetes.
RESEARCH DESIGN AND METHODS
The Finnish Diabetic Nephropathy (FinnDiane) study is an ongoing nation-
wide prospective multicenter study established to identify risk factors for type
1 diabetes and its complications. The FinnDiane registry has been described
in detail in previous publications (7,8). In brief, between January 1997 and
April 2006, 4,201 adults with type 1 diabetes were recruited from 21 university
and central hospitals, 33 district hospitals, and 26 primary health care centers
across Finland. The mean response rate was 78%. Type 1 diabetes was deﬁned
by insulin dependence within 1 year of diagnosis, the absence of circulating
C-peptide (0.3 nmol/l), and an age of onset of 35 years. Every participant
gave written informed consent. The study was approved by ethics committees
of participating centers and conducted in accordance with the Helsinki
Declaration.
Characteristics of the subjects. Data on smoking habits, alcohol intake,
educational level and social class were obtained using a patient questionnaire.
Details on clinical status, including age at diagnosis, insulin therapy, and other
regular medications, together with presence, severity, and management of
diabetic complications, including retinopathy and macrovascular disease,
were obtained from medical records by the attending physician using a
standardized questionnaire. The presence of proliferative retinopathy was
arbitrarily deﬁned by the previous use of laser treatment. The presence of
preexisting macrovascular disease was deﬁned in individuals with a clinical
history of myocardial infarction, unstable angina requiring hospitalization,
coronary revascularization, stroke, carotid surgery, peripheral revasculariza-
tion, and amputation for critical limb ischemia.
Fasting blood samples were obtained for the measurement of A1C, lipids,
and creatinine. The glomerular ﬁltration rate (GFR) was estimated using the
abbreviated Modiﬁcation of Diet in Renal Disease (MDRD) equation (9).
Baseline urinary albumin excretion (UAE) was stratiﬁed according to Inter-
national Diabetes Federation guidelines (10), such that microalbuminuria was
deﬁned by a UAE of 20–200 g/min, macroalbuminuria by a UAE 200
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DIABETES, VOL. 58, JULY 2009 1651g/min, and normoalbuminuria by a UAE 20 g/min in two of three
consecutive urine collections. The presence of chronic kidney disease was
deﬁned, according to DOQI (Dialysis Outcomes Quality Initiative) guidelines,
by the presence of either microalbuminuria, macroalbuminuria, an estimated
GFR 60 ml/min per 1.73 m
2, or end-stage kidney disease (9).
Blood pressure measurements were performed twice in the sitting posi-
tion, with a 5-min interval between testing. Hypertension was deﬁned by
antihypertensive medication use or a blood pressure greater than target levels
of 130/85 mmHg over two readings in an untreated individual.
Ascertainment of outcomes. The primary outcome was death from any
cause through to the 1st of April 2007. Deaths were identiﬁed via a search of
the Finnish National Death Registry and center databases. All deaths were
conﬁrmed with death certiﬁcate data. Expected mortality was estimated from
general population life tables (Tilastokeskus, Helsinki, Finland) using person-
year methods. Age- and sex-adjusted standardized mortality ratios (SMRs)
were estimated by dividing the observed number of deaths by the expected
number of deaths in each age and sex category.
Statistical analysis. To evaluate the independent predictors of mortality in
individuals with type 1 diabetes, we used Cox proportional-hazards models in
both the total cohort and selected subgroups. All variables known to be
associated with mortality were included in the ﬁnal models, along with any
variables associated with mortality in univariate analyses with a P value
0.01. In each case, model selection from candidate variables was accom-
plished by minimization of the Akaike and Bayesian information criteria (11).
Baseline UAE was entered as a categorical variable (normoalbuminuria,
microalbuminuria, and macroalbuminuria). The potential for multiple colin-
earity was tested using the variance inﬂation factor and condition number,
where a variance inﬂation factor 10 and condition number 30 are desirable
(12). Covariate functional form (including assessment of nonlinear effects)
was judged by residual-by-time analysis, fractional polynomials (13), and
(cubic) regression splines (14). Overall, Cox model ﬁt was assessed by 1)
approximation of cumulative Cox-Snell residuals to (-log) Kaplan-Meier
estimates, residual plots, and speciﬁc testing of the proportional hazards
assumption (15) and 2) Harrell’s C statistic (16) and “added-variable” good-
ness-of-ﬁt tests (17). Cox model performance was judged by the explained
variation using 5,000 bootstrap repetitions of the whole dataset, adjusting for
covariates (18). Analyses were conducted with the use of Stata statistical
software (version 10.0, 2007; StataCorp, College Station, TX) and SPSS
software (version 13.0; SPSS, Chicago, IL).
RESULTS
Cohort characteristics. FinnDiane recruited 4,201 adults
with type 1 diabetes, equivalent to 16% of patients with
type 1 diabetes in Finland (Table 1). At baseline, 504
individuals (12%) had UAE in the microalbuminuric range,
578 individuals (14%) had UAE in the macroalbuminuric
range, and 293 individuals (7%) were receiving renal
replacement therapy, including 72 individuals on dialysis
and 221 individuals with a functioning kidney transplant. A
total of 2,296 individuals (55%) had UAE in the normoalbu-
minuric range. A further 13% of study participants were
unclassiﬁed (n  530) because of an inadequate number of
urine collections (3). The clinical characteristics of these
individuals were intermediate between those with nor-
moalbuminuria and those with microalbuminuria (data not
shown). In individuals not receiving renal replacement
therapy, 14% (n  462) had an estimated GFR 60 ml/min
per 1.73 m
2. The characteristics of these patients are
shown in Table 2. When the number of individuals with an
estimated GFR 60 ml/min per 1.73 m
2 were added to
micro- or macroalbuminuria and those receiving renal
replacement therapy, 33% of study participants had
chronic kidney disease. In addition, over half (57%) had
established retinopathy, 63% of whom had received laser
therapy for proliferative changes. In addition, 10% of the
cohort had established macrovascular disease.
TABLE 1
Baseline characteristics of FinnDiane study participants, stratiﬁed according to UAE*
Normoalbuminuria Microalbuminuria Macroalbuminuria ESKD
n 2,296 504 578 293
Age (years) 36  12 38  12* 41  10* 44  8*
Male sex 1,088 (47) 296 (59)† 338 (58)† 178 (61)†
Duration of diabetes (years) 20  12 26  11* 29  8* 32  8*
Insulin dose (IU/kg) 0.7  0.2 0.7  0.3 0.7  0.2 0.8  0.4
Insulin injections/day 4.8  1.0 4.8  1.0 4.5  1.0* 4.2  1.0*
A1C (%) 8.2  1.4 8.8  1.5* 9.0  1.5* 8.6  1.6
Estimated glucose disposal rate (mg 
kg
1  min
1)‡ 7.3  2.2 5.1  2.0* 4.0  1.6* 4.0  1.6*
Hypertension 1,344 (59) 444 (88) 557 (96) 288 (97)
Systolic blood pressure (mmHg) 129  15 136  16* 145  20* 153  25*
Diastolic blood pressure (mmHg) 78  98 0  10* 83  10* 86  13*
Medication use
ACE inhibition 204 (9) 271 (54)† 425 (75)† 61 (21)
Angiotensin receptor blocker 44 (2) 42 (8)† 75 (13)† 31 (5)†
Calcium channel blocker 60 (3) 40 (8)† 208 (36)† 163 (56)†
-Blocker 90 (4) 46 (9)† 190 (33)† 188 (64)†
Other antihypertensive agents 64 (3) 48 (10)† 282 (49)† 170 (58)†
Lipid-lowering therapy 135 (6) 49 (10)† 137 (23)† 76 (26)†
Total cholesterol (mmol/l) 4.8  0.9 5.0  0.9 5.4  1.1 5.5  1.2
LDL cholesterol (mmol/l) 3.0  0.8 3.1  0.8 3.5  0.9 3.5  1.1*
HDL cholesterol (mmol/l) 1.1  0.4 1.3  0.4 1.3  0.4 1.3  0.4
Triglycerides (mmol/l) 1.1  0.7 1.3  0.9 1.7  1.2 1.7  0.9*
Any retinopathy 889 (39) 382 (76)† 547 (95)† 290 (99)†
Retinopathy requiring laser therapy 340 (15) 241 (48)† 460 (80)† 288 (97)†
Current smoker 491 (21) 153 (30) 164 (29) 49 (16)
Established macrovascular disease 88 (4) 37 (7)† 105 (18)† 138 (47)†
Estimated GFR 60 ml/min per 1.73 m
2 73 (3) 45 (9)† 354 (61)† N/A
Data are the means  SD or n (% deaths). To convert values for cholesterol to milligrams per deciliter, divide by 0.2586. *P value versus
patients with normoalbuminuria 0.05, calculated by Student’s t test; †P value versus patients with normoalbuminuria 0.05, calculated by

2; ‡a measure of insulin sensitivity using the formula proposed by Williams et al. (43). ESKD, end-stage kidney disease.
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Median follow-up was 7 years, totaling 26,863 patient-years
of surveillance, during which time there were 291 deaths
(7%, 1.1 per 100 person-years). This mortality rate was 3.6
times higher (95% CI 3.2–4.0) than in the age- and sex-
matched general population. Excess mortality associated
with type 1 diabetes was more pronounced among women
(adjusted SMR 4.8, 95% CI 4.0–5.8) than among men (3.0,
2.6–3.5; sex difference P  0.001), eliminating the sex
difference in mortality, as previously described (19). The
distribution of the listed primary cause of death is shown
in Table 3.
Chronic kidney disease and mortality in type 1 dia-
betes. The presence and severity of chronic kidney dis-
ease was the major predictor of all-cause mortality in the
FinnDiane cohort (Fig. 1A and B, Fig. 2, and the supple-
mental table, which is available in an online appendix at
http://diabetes.diabetesjournals.org/cgi/content/full//db08-
1543/DC1). Indeed, excess mortality, beyond that ob-
served in the age-and sex-matched general population,
was only demonstrated in individuals with chronic kidney
disease (Fig. 2). Mortality in the FinnDiane participants
without chronic kidney disease (66% of the total cohort)
was not signiﬁcantly different compared to that observed
TABLE 2
Baseline characteristics of FinnDiane study participants stratiﬁed according to estimated GFR*
120 60–120 60 ESKD
n 272 2,699 462 293
Age (years) 28  10* 37  12 44  10* 44  8*
Male sex 194 (71)† 1,320 (49) 214 (46) 178 (61)†
Duration of diabetes (years) 17  11 20  12 30  9* 32  8*
Insulin dose (IU/kg) 0.8  0.2 0.7  0.2 0.6  0.2 0.8  0.4
Insulin injections/day 4.9  1.0 4.8  1.0 4.5  1.0* 4.2  1.0*
A1C (%) 8.6  1.6 8.4  1.5 8.8  1.5* 8.6  1.6
Estimated glucose disposal rate (mg  kg
1  min
1)‡ 7.9  2.0 7.3  2.2 4.6  2.0* 4.0  1.6*
Hypertension 176 (65) 1,888 (70) 444 (96)† 288 (97)†
Systolic blood pressure (mmHg) 128  14 132  16 145  20* 153  25*
Diastolic blood pressure (mmHg) 78  97 9  98 1  10* 86  13*
Medication use
ACE inhibition 30 (11)† 611 (23) 294 (64)† 61 (21)
Angiotensin receptor blocker 3 (1)† 118 (4) 55 (12)† 31 (5)†
Calcium channel blocker 2 (1)† 134 (5) 177 (39)† 163 (56)†
-Blocker 1 (0)† 150 (6) 185 (40)† 188 (64)†
Other antihypertensive agents 1 (0)† 154 (6) 219 (47)† 170 (58)†
Lipid-lowering therapy 11 (4)† 206 (8) 123 (27)† 76 (26)†
Total cholesterol (mmol/l) 4.9  0.9 4.9  0.9 5.3  1.0* 5.5  1.2*
LDL cholesterol (mmol/l) 3.0  0.8 3.0  0.8 3.5  1.0* 3.5  1.1*
HDL cholesterol (mmol/l) 1.4  0.4* 1.1  0.4 1.3  0.4* 1.3  0.4*
Triglycerides (mmol/l) 1.2  0.7 1.2  0.8 1.7  1.2* 1.7  0.9*
Any retinopathy 76 (29)† 1,313 (50) 420 (93)† 290 (99)†
Retinopathy requiring laser therapy 27 (10)† 683 (25) 360 (78)† 288 (97)†
Current smoker 98 (37)† 614 (24) 95 (22) 49 (16)†
Established macrovascular disease 31 (11)† 123 (5) 116 (25)† 138 (47)†
Macroalbuminuria 2 (3)† 210 (8) 338 (73)† N/A
Microalbuminuria 2 (5)† 405 (15) 37 (8)† N/A
Data are n (% deaths) or means  SD. To convert values for cholesterol to milligrams per deciliter, divide by 0.02586. *P  0.05 vs. patients
with an estimated GFR 60–120, calculated by Student’s t test; †P  0.05 vs. patients with an estimated GFR 60–120, calculated by 
2;
‡a measure of insulin sensitivity using the formula proposed by Williams et al. (43). ESKD, end-stage kidney disease.
TABLE 3
Primary cause of death of FinnDiane study participants stratiﬁed according to UAE and estimated GFR
n
Primary cause of death All cause
[n (% cohort)] Cardiovascular Cancer Infection Other causes
UAE
Normoalbuminuria 2,296 14 (47) 2 (7) 2 (7) 12 (40) 30 (1.3)
Microalbuminuria 504 15 (56)* 1 (4) 3 (11)* 7 (30)* 26 (5.2)*
Macroalbuminuria 578 40 (45)* 3 (3)* 18 (20)* 28 (31)* 89 (15.4)*
ESKD 293 78 (58)* 7 (5)* 24 (18)* 26 (19)* 135 (46.1)*
Estimated GFR
120 272 5 (42) 1 (8) 1 (8) 5 (42) 12 (4.4)†
60–120 2,699 28 (46) 3 (5) 8 (13) 22 (36) 61 (2.3)
60 462 42 (51)† 3 (4)† 15 (18)† 22 (27)† 82 (17.7)†
ESKD 293 78 (58)† 7 (5)† 24 (18)† 26 (19)† 135 (46.1)†
Data are n (% deaths), unless otherwise noted. *P value 0.05 vs. patients with normoalbuminuria 0.05, calculated by 
2;† P value 0.05
vs. patients with an estimated GFR 60–120 ml/min per 1.73 m
2, as calculated by 
2. ESKD, end-stage kidney disease.
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0.5–1.1), regardless of the duration of their diabetes.
The impact of each stage of diabetic kidney disease
on mortality across the total cohort was equivalent to
the presence of preexisting macrovascular disease (ad-
justed hazard ratio 2.5, 95% CI 1.7–3.7). In addition, the
survival in individuals with both macrovascular disease
and chronic kidney disease was signiﬁcantly reduced
compared with individuals with either condition alone,
and not signiﬁcantly different from that observed in
individuals receiving renal replacement therapy. Whereas
dyslipidemia, insulin sensitivity, and hypertension were
strongly linked to chronic kidney disease in this cohort
(Table 1), the association between chronic kidney dis-
ease and mortality was independent with respect to the
achieved control and the use and intensity of therapies,
including statins and blockade of the renin-angiotensin
system (RAS), although such associations may be con-
founded by indication.
The estimated GFR was also associated with all-cause
mortality (P  0.001), independent of the level of UAE,
macrovascular disease, and other baseline factors. The
relationship between estimated GFR and mortality exhib-
ited nonlinearity and was characterized using a regression
spline (Fig. 3A). Mortality was increased in individuals
with an estimated GFR 60 ml/min per 1.73 m
2 (adjusted
hazard ratio 1.7, 95% CI 1.1–2.6) (Fig. 1B). In addition,
individuals with an estimated GFR 120 ml/min per 1.73
m
2 also displayed increased mortality, independent of the
presence or severity of albuminuria (Fig. 1B).
A history of proliferative retinal disease (deﬁned by the
previous requirement for laser therapy) was also associ-
ated with increased mortality in the FinnDiane cohort
(Fig. 1C). However, this association was eliminated after
adjusting for baseline albuminuria. Because proliferative
retinopathy and markers of diabetic kidney disease are
strongly associated in this cohort (Table 1), and indeed
may be considered manifestations of the same microangi-
opathy, it may not be appropriate from either a physiolog-
ical or a statistical point of view to include retinopathy and
chronic kidney disease in the same multiple regression
analyses. In the absence of proliferative changes, back-
ground retinopathy was not associated with mortality in
this cohort (Fig. 1C).
Mortality in individuals with end-stage kidney dis-
ease and in type 1 diabetes. Of all the individuals with
end-stage kidney disease, 46% died during the follow-up
period (135 of 293). This mortality was 18.3 times that
observed in the general population (95% CI 15.8–22.1).
Mortality was highest in individuals on dialysis (68%)
compared with those with a functioning kidney transplant
(39%, P  0.001). The independent predictors of mortality
in individuals on dialysis (49 of 72) were the years on
dialysis (adjusted hazard ratio, per year, 1.4, 95% CI
1.2–1.7) and the pulse pressure (per 10 mmHg, 1.3, 1.0–
1.5). Glycemic control in individuals on dialysis was not
associated with all-cause mortality. In individuals with a
functioning renal transplant (86 of 221), the duration of
diabetes (decades, adjusted hazard ratio 2.6, 95% CI 1.8–
3.7) and A1C (1.3, 1.1–1.5) were predictors of all-cause
mortality. In addition, individuals with impaired graft
function characterized by an estimated GFR 60 ml/min
per 1.73 m
2 were over twice as likely to have died during
follow-up than those with preserved graft function (ad-
justed hazard ratio 2.4, 95% CI 1.3–4.1).
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FIG. 1. Survival plots showing Cox-adjusted survival of individuals with
type 1 diabetes from the FinnDiane study, stratiﬁed for the presence and
severity of albuminuria (A), estimated GFR (B), and the presence and
severity of retinopathy (C) at baseline. All ﬁgures are adjusted for age;
sex; duration of diabetes; body habitus; the presence and extent of macro-
and microvascular complications; glycemic, lipid, and blood pressure
control; and drug management. The latter ﬁgure (C) is not adjusted for
the presence and severity of nephropathy, as discussed in the text.
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individuals with macroalbuminuria, 15% (89 of 578) died
during the follow-up period. This mortality rate was over
nine times that observed in the age- and sex-matched
general population (adjusted SMR 9.2, 95% CI 8.1–10.5).
The major independent predictors of all-cause mortality in
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FIG. 3. Relationship of estimated GFR to the hazard ratio for mortality in individuals with type 1 diabetes without end-stage kidney disease from
the total FinnDiane cohort (A) and in individuals with normoalbuminuria (B), microalbuminuria (C), and macroalbuminuria (D). Dotted line
shows point estimate for cubic regression spline adjusted for other predictive variables. Gray area denotes 95% CI.
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betes (decades, adjusted HR 1.6, 95% CI 1.2–2.1) and the
presence of preexisting macrovascular disease (2.1, 1.2–
3.4) and A1C (1.3, 1.2–1.5). In addition, individuals with
macroalbuminuria and an estimated GFR 60 ml/min per
1.73 m
2 were twice as likely to have died during follow-up
as those with preserved kidney function (2.0, 1.1–3.4),
independent of other baseline risk factors and the use of
preventive therapies (Fig. 3B). The presence of a reduced
estimated GFR was equivalent (in terms of mortality risk)
to that of preexisting macrovascular disease.
Mortality in individuals with microalbuminuria. In
individuals with microalbuminuria, 5.2% (26 of 504) died
during follow-up. This mortality rate was over twice that
observed in the general population (adjusted SMR 2.8, 95%
CI 2.0–4.2). The major independent predictors of all-cause
mortality in microalbuminuria were the duration of diabe-
tes (decades, adjusted HR 2.0, 95% CI 1.3–3.0) and the
presence of preexisting macrovascular disease (6.0, 2.4–
14.5). All-cause mortality was not signiﬁcantly associated
with treatments, the achieved level of blood pressure, or
lipid levels. The estimated GFR was also independently
associated with mortality risk (P  0.01). This relationship
was nonlinear and was characterized using a regression
spline (Fig. 3C). Individuals with microalbuminuria and
estimated GFR 60 ml/min per 1.73 m
2 (8%) were more
likely to have died during follow-up than those with
preserved kidney function (unadjusted mortality 18 vs. 4%,
P  0.01). Equally, individuals with microalbuminuria and
an estimated GFR 120 ml/min per 1.73 m
2 had increased
mortality compared with those with normal renal function
(unadjusted mortality 7 vs. 3%, P  0.01).
Mortality in individuals with normoalbuminuria. In
individuals with normoalbuminuria, only 1.3% (30 of 2,296)
died during follow-up. This rate was not signiﬁcantly
different from the general population (adjusted SMR 0.8,
95% CI 0.5–1.1) and was independent of the duration of
diabetes. The major independent predictors of mortality in
individuals with normoalbuminuria were age (decades,
adjusted HR 1.7, 95% CI 1.2–2.4) and the presence of
preexisting macrovascular disease (6.7, 2.5–17.6). Again,
mortality in these individuals was not associated with lipid
levels or blood pressure control. However, the estimated
GFR was independently associated with mortality (P 
0.001). The relationship between estimated GFR and the
hazard ratio for mortality in individuals with normoalbu-
minuria again exhibited nonlinearity (Fig. 3D). Although
3% of individuals with normoalbuminuria had an esti-
mated GFR 60 ml/min per 1.73 m
2, signiﬁcantly more of
these individuals died during follow-up than those with
normal kidney function (unadjusted mortality 5 vs. 1%, P 
0.01). In addition, individuals with an estimated GFR 120
ml/min per 1.73 m
2 also displayed increased mortality
compared with those with normal renal function (unad-
justed mortality 3 vs. 1%, P  0.01).
Mortality and glycemic control in type 1 diabetes.
Glycemic control is an important target for the manage-
ment of individuals with type diabetes. In FinnDiane
participants not receiving renal replacement therapy, gly-
cemic control, as estimated by the A1C, was independently
and continuously associated with all-cause mortality (ad-
justed HR 1.3, 95% CI 1.2–1.4). However, the relationship
between A1C and the hazard for mortality exhibited some
nonlinearity and was modeled as a multivariate cubic
spline (Fig. 4). Notably, there was no difference in the
relationship between A1C and mortality risk across differ-
ent subgroups of albuminuria (interaction P  0.34).
Insulin resistance has also been associated with cardio-
vascular disease in individuals with type 1 diabetes (20),
although this relationship is confounded by the strong
association between the insulin sensitivity and chronic
kidney disease in type 1 diabetes (7). In the FinnDiane
cohort, insulin sensitivity, as measured by the estimated
glucose disposal rate (20), was inversely associated with
all-cause mortality (P  0.001), independent of age, dura-
tion of diabetes, and glycemic control. However, this
association was eliminated after adjusting for the presence
and severity of chronic kidney disease (P  0.9).
DISCUSSION
In a large sample of adults with type 1 diabetes from
Finland, an independent, graded association was observed
between the presence and severity of chronic kidney
disease and all-cause mortality. In this population, excess
mortality associated with type 1 diabetes was only ob-
served in individuals with chronic kidney disease (Fig. 2),
whereas mortality in participants without chronic kidney
disease (66% of the total cohort) was identical to the
general population. These results from a stable, nationally
representative cohort of adults with type 1 diabetes com-
plement and extend evidence from the last 2 decades
showing the link between mortality and chronic kidney
disease (3–6). These ﬁndings highlight the continuing
clinical and public health importance of chronic kidney
disease and its prevention in the management of type 1
diabetes.
Our ﬁndings in individuals with type 1 diabetes are
analogous to the relation between chronic kidney disease
and mortality previously described in individuals with type
2 diabetes (21) and in nondiabetic individuals (22).The
observed association between chronic kidney disease and
mortality can be explained by several plausible mecha-
nisms. It has been suggested that kidney damage in
individuals with type 1 diabetes reﬂects more generalized
damage to the cardiovascular system leading to cardiovas-
cular disease and subsequently mortality (23). The associ-
ation of mortality with proliferative retinopathy (Fig. 1C)
may be explained in the same way. However, impaired
kidney function may also directly contribute to hyperten-
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FIG. 4. Relationship of A1C to the hazard ratio for mortality in
individuals with type 1 diabetes without end-stage kidney disease.
Dotted line shows point estimate for the cubic regression spline
adjusted for other predictive variables. Gray area denotes 95% CI.
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tion (8), dyslipidemia (25), elevated plasma homocysteine
(26), the accumulation of advanced glycation end products
(27), anemia (28), left ventricular hypertrophy (29), arterial
calciﬁcation (30), and endothelial dysfunction (31). Chronic
kidney disease is also associated with impaired immune
function, which, alongside vascular compromise, probably
contributed to the increased frequency of death from infec-
tion observed in those with chronic kidney disease.
The observed hazards associated with each stage of
kidney disease are similar to those reported in cohort
studies 20 years ago (3–6), although the absolute mor-
tality in the FinnDiane cohort is signiﬁcantly lower. Al-
though it is possible to argue that improvements in
diabetic management have not led to changes in the
relative risk of mortality in individuals with chronic kidney
disease, there is little doubt that the absolute risk reduc-
tion has been considerable over this time period, via the
prevention of chronic kidney disease, and the manage-
ment of individuals with proteinuria (32) and/or macrovas-
cular disease, who carry the majority of the risk burden.
However, the contemporary hazard associated with
chronic kidney disease demonstrated in this study empha-
sizes that more remains to be done to address this
enhanced risk beyond currently available regimens.
This study also demonstrates that estimated GFR is an
independent risk factor for mortality in type 1 diabetes.
Regardless of the level of albuminuria, those with an
estimated GFR 60 ml/min per 1.73 m
2 were twice as
likely to have died during follow-up. In addition, an
elevated estimated GFR was also associated with in-
creased mortality (Fig. 1B), which was identiﬁed by non-
linear analysis (Fig. 3). Although it should be noted that
the MDRD equation overestimates renal function in this
range and that the ability of this formula to discriminate
hyperﬁltration from normal function is suboptimal (33),
particularly as a single measurement, it was nonetheless
able to stratify mortality risk. In so far as hyperﬁltration
precedes progressive kidney disease (34,35), this associa-
tion is not surprising, and probably reﬂects early patho-
logical changes both in the kidney and in other parts of the
vasculature.
Although hyperglycemia has been implicated in the
development of microvascular complications in type 1
diabetes, an association between glycemic control and
mortality has only been observed in some (36), but not all
studies (20,37). In the FinnDiane cohort, glycemic control
was also independently associated with all-cause mortality
(Fig. 4). A signiﬁcant association between A1C and mor-
tality was also present in individuals with a kidney trans-
plant, consistent with previous reports (38). However,
when modeled as a linear variable, no clear association
was observed between A1C and mortality in individuals
with normo- or microalbuminuria (P  0.38). It is possible
that this reﬂects a type II error due to the lower number of
deaths in these subgroups. However, when modeled as a
multivariate cubic spline (Fig. 4), there was no interaction
between A1C and albuminuria (P  0.34) in determining
mortality, suggesting the impact of poor glycemic control
is homogeneous across all levels of albuminuria.
Strengths of our study include its large cohort of indi-
viduals with type 1 diabetes, high participation rate, access
to subsidized care (75–100% of costs), and contemporary
treatment regimens, including a range of insulin regimens,
statins, blockers of the RAS, and self-monitoring technol-
ogies. Our methods of measuring UAE and serum creati-
nine were reliable, validated centrally using standardized
methodologies. We used validated methods to identify
deaths, and all deaths in our cohort were conﬁrmed
through death records. Surveillance bias is unlikely, given
the uniform vital status follow-up procedures used by our
staff masked to participants’ chronic kidney disease status
levels. In our questionnaire, we had broad data on tobacco
or alcohol use, diet, education, socioeconomic status,
other possible confounders (e.g., insulin resistance), or the
severity of disease (e.g., level of blood pressure). Finally,
few changes in diabetes treatment and health care over the
short study period will have affected mortality results.
Several study limitations need to be considered. First,
our study results may not be generalizable because of
selection bias in enrollment and subsequently in ascertain-
ment. Our study was conducted among adults with long-
standing diabetes. Consequently, our results may reﬂect
past management practices that are less generalizable to
adults with newly diagnosed diabetes. These studies were
also limited by the use of broad deﬁnitions of diminished
kidney function and the inclusion of relatively small
numbers of subjects with renal impairment, thus reducing
the statistical power to examine different levels of reduced
estimated GFR. It is also likely that our clinical history was
not sufﬁciently sensitive to accurately discriminate be-
tween the presence or absence of macrovascular disease
in this population, given that diabetes is often associated
with silent ischemia and that subjects with type 1 diabetes
can often have a normal resting electrocardiogram and
still have suffered a previous myocardial infarction or have
signiﬁcant coronary lesions (39). Such standardized exer-
cise testing and/or coronary imaging was not feasible in a
large study such as FinnDiane. Consequently, the true
contribution of underlying macrovascular disease to the
observed changes in mortality cannot be ascertained in
this study. Nonetheless, a reliance on clinical history is
potentially more representative of the true clinical setting.
Changes in medications and risk factor control during
follow-up cannot be controlled for. Finally, it is possible
that our results were biased by residual confounding by
factors not measured in the study but potentially related to
cardiovascular disease/mortality in type 1 diabetes, includ-
ing silent cardiovascular disease, lipoprotein subclasses
(40), oxidative stress (41), and endothelial (31) and auto-
nomic dysfunction (42).
In conclusion, results from our study clearly demon-
strate that chronic kidney disease is the dominant contrib-
utor to excess mortality in type 1 diabetes. Consequently,
if you have type 1 diabetes, prevention of chronic kidney
disease is currently the best way to reduce your risk of a
premature death. Modern multifactorial therapeutic ap-
proaches, such as those detailed in American Diabetes
Association guidelines, are effective in preventing the
development of kidney disease. For those with established
chronic kidney disease, more intensive multifactorial in-
terventions are also valuable in reducing the progression
of chronic kidney disease, and, with it, mortality.
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